A small wireless device placed inside the eye may help restore vision for people who have lost their sight because of a serious eye disease. Researchers recently reported that this tiny retinal implant helped many patients recover part of their central vision.
The findings were published in the New England Journal of Medicine and are giving new hope to people living with advanced age-related macular degeneration.
Age-related macular degeneration, often called AMD, is one of the most common causes of vision loss among older adults. The disease mainly affects the macula, which is the small central part of the retina responsible for sharp, detailed vision.
The retina is the thin layer of tissue at the back of the eye that senses light and sends signals to the brain. When the macula becomes damaged, people gradually lose their ability to see clearly in the center of their vision. This makes everyday activities such as reading, recognizing faces, or seeing road signs very difficult.
One severe form of the disease is called geographic atrophy, or GA. In this condition, important cells in the retina slowly die and cannot be replaced. Over time, this damage causes permanent loss of central vision. Worldwide, more than five million people are affected by this stage of AMD, and many eventually become legally blind.
Because the damaged retinal cells cannot grow back naturally, doctors have struggled to find ways to restore lost vision. For many years, treatments could only slow the disease rather than repair the damage that had already occurred.
Now, scientists from several international research centers have tested a new approach using a tiny wireless retinal implant called PRIMA. The clinical study was led by Dr. José-Alain Sahel of the UPMC Vision Institute, Dr. Daniel Palanker from Stanford University, and Dr. Frank Holz from the University of Bonn in Germany.
In the study, researchers followed patients who received the implant and tracked their vision over time. A total of 38 participants aged 60 and older joined the trial. They were treated at 17 medical centers across five European countries: France, Germany, Italy, the Netherlands, and the United Kingdom.
Thirty-two participants completed a full year of follow-up after receiving the device. The results showed that many patients experienced meaningful improvements in their vision. Twenty-six of the participants, or about 81 percent, gained noticeable improvement in their visual acuity. Visual acuity is a measure of how clearly someone can see letters or objects at a certain distance.
On average, participants improved by 25 letters on a standard eye chart when using the implant. This improvement is equal to about five lines on the chart. In addition, more than 80 percent of patients improved by at least 10 letters.
Many patients were also able to use the device in everyday life. Twenty-seven participants said they were using the artificial vision from the implant at home to read numbers or short words. Some patients even managed to read longer text, including parts of book pages.
The implant works by replacing the function of the photoreceptors that are destroyed by AMD. In a healthy eye, photoreceptors capture light and convert it into electrical signals. These signals travel through nerve cells and then through the optic nerve to the brain, where the brain interprets them as images.
When AMD damages the photoreceptors, the retina can no longer detect light properly. However, many of the deeper retinal nerve cells remain alive. The PRIMA implant takes advantage of these surviving cells.
The device itself is extremely small, measuring only about two millimeters by two millimeters. It is placed under the retina in the area where the damaged photoreceptors once worked.
Patients wear special glasses that contain a small camera. The camera captures images from the surrounding environment and sends them to the implant using invisible near‑infrared light.
The implant then converts the light signals into electrical pulses that stimulate the remaining retinal cells. These signals travel through the optic nerve to the brain, allowing the patient to perceive visual patterns.
The glasses also allow users to adjust zoom and contrast, helping them better identify letters or shapes.
Importantly, the researchers reported that side effects from the procedure were manageable. After one year, all side effects related to the surgery had resolved.
One patient in the study experienced an especially strong improvement, gaining 59 letters on the eye chart. This corresponds to about 12 lines of improvement, which is considered a large change in vision.
Although the technology cannot yet restore perfect eyesight, the results represent a major step forward. According to the researchers, this is the first time that a vision restoration device has produced such consistent improvements in a large group of patients.
The device is currently under review by regulatory authorities. The manufacturer, Science Corporation, has submitted applications seeking approval for clinical use in both Europe and the United States.
Researchers are continuing to study ways to improve the system further. Future developments may include combining the implant with other technologies to enhance visual detail and expand the field of vision.
When reviewing the findings, several important points become clear. First, the study shows that even when photoreceptor cells are lost, it may still be possible to restore partial vision by stimulating the remaining retinal network. This challenges the long‑held belief that advanced AMD always leads to irreversible blindness.
Second, the study highlights how advances in biomedical engineering and neuroscience can work together to solve medical problems. By combining microelectronics, optics, and knowledge of retinal biology, scientists have created a device that can replace part of the natural visual system.
However, it is also important to recognize the limitations. The implant does not restore normal vision, and patients must rely on specialized glasses and training to use the system effectively. In addition, the trial involved a relatively small number of participants, so larger studies will be needed to confirm the results and evaluate long‑term safety.
Despite these challenges, the research represents a promising breakthrough for people with advanced macular degeneration. If future studies confirm the benefits and regulators approve the technology, retinal implants like PRIMA could become an important new option for restoring functional vision in patients who previously had no treatment choices.
If you care about eye health, please read studies about how vitamin B may help fight vision loss, and MIND diet may reduce risk of vision loss disease.
For more information about eye disease, please see recent studies about how to protect your eyes from glaucoma, and results showing this eye surgery may reduce dementia risk.
The study is published in the New England Journal of Medicine.
Copyright © 2026 Knowridge Science Report. All rights reserved.
